Calendario›SNY›Burden of Respiratory Syncytial Virus (RSV) in Children in Sweden (BRICS): A Retrospective Study in Sweden
Burden of Respiratory Syncytial Virus (RSV) in Children in Sweden (BRICS): A Retrospective Study in Sweden
Ensayo de Sanofi en Infeccion por virus respiratorio sincitial.
Más ensayos de: Infección por virus respiratorio sincitial.
- Fase
- no aplica
- Estado
- Completado
- Participantes
- 1.100.000
- Fin del objetivo primario
- abr 2024
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio observacional. Comenzó en jul 2006.
Qué mide
Short-term healthcare: Number of specialist outpatient visits (Analysis period: July 1st 2006 - July 31st 2021 Reporting period: 30 days from index date) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroPrimary Objective: -Estimate the hospital-associated healthcare resource use (HCRU), and associated costs, of RSV infection in children in comparison to the non-RSV control cohort (general population) and patients with rhinovirus infection. Secondary Objectives: * Describe demographic and clinical patient characteristics of RSV infected children. * Estimate and compare the incidence of RSV infection and acute respiratory infections (ARIs) in children. * Estimate the mortality associated with RSV infection in children. * Estimate the social economic burden of RSV infection in children in relation to parents staying home from work to care for their sick child (VAB leave) in comparison to non-RSV control cohort (i.e. parents to children in the general population). * Estimate the net days with VAB leave and the compensation disbursed (temporary parental benefit) associated with RSV infection in children. * Estimate the indirect costs that can be attributed to VAB leave. * Examine the medium- and long-term complications associated with an RSV diagnosis in children in comparison to the non-RSV control chart (general population) and patients with rhinovirus infection. * Examine and describe risk factors associated with an RSV infection in children * Estimate the healthcare resource use (HCRU), and associated costs, of RSV infection in children, for a subset of patients where primary care data is available, in comparison to the non-RSV control cohort (general population).
Más ensayos de SNY
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Avalglucosidase alfa · Mini-COMET | Fase 2 | En marcha, sin reclutar | sep 2019 (real) |
| Yellow fever vaccine | Fase 2 | En marcha, sin reclutar | may 2022 (real) |
| Yellow fever vaccine · VYF02 | Fase 2 | En marcha, sin reclutar | jun 2022 (real) |
| SAR441344 IV | Fase 2 | En marcha, sin reclutar | sep 2022 (real) |
| Meningococcal Polysaccharide | Fase 3 | En marcha, sin reclutar | mar 2023 (real) |
| Isatuximab IV · IRAKLIA | Fase 3 | En marcha, sin reclutar | nov 2024 (real) |
Todos los de SNY, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT05622331), actualizada en may 2024.